Zinc eases insulin resistance, with an LDL catch

Zinc plays a central biological role in insulin synthesis, storage and signalling, and in the body's antioxidant defences, which makes it a plausible candidate for supporting metabolic health in diabetes. Diabetes itself is characterised by insulin resistance, impaired insulin secretion and a raised inflammatory and cardiometabolic burden. Despite the strong mechanistic rationale, trials of zinc supplementation have produced results whose clinical relevance and consistency remained uncertain. This review set out to pool the randomised evidence and establish what zinc supplementation actually changes in people with diabetes, gestational diabetes or prediabetes.

The authors systematically searched PubMed/MEDLINE, Web of Science, Scopus, CINAHL and Google Scholar for randomised controlled trials of zinc supplementation in people with diabetes, gestational diabetes or prediabetes. Eighteen trials met the eligibility criteria, together enrolling 1023 participants. Outcomes covered glycaemic control and insulin resistance, blood lipids, and markers of inflammation and oxidative stress. The review was registered in advance on the PROSPERO database.

Zinc supplementation raised plasma zinc concentrations (a mean difference of 7.80) and improved insulin resistance, with serum insulin falling by 2.50 and the HOMA-IR score by 1.10. Total cholesterol dropped modestly but significantly, by 5.70, which the authors note is a relatively small absolute reduction. LDL cholesterol, however, showed a modest increase of 3.46, and the clinical relevance of that rise is uncertain. Inflammation and oxidative stress also moved favourably: C-reactive protein and malondialdehyde both fell, while total antioxidant capacity increased.

The findings support the long-standing biological case that zinc status is entangled with insulin function, and they line up with the idea that supplementation can shift laboratory markers in a favourable direction. At the same time, the divergent lipid results complicate the story: total cholesterol fell while LDL rose, and the review cannot say what either change means for actual health outcomes. The open questions are whether these marker improvements translate into fewer complications, and who, if anyone, benefits most.

For readers interested in metabolic health, this is a reason to think zinc is more than a bystander in insulin function: across a thousand trial participants, supplementation moved insulin resistance, inflammation and oxidative stress markers in the right direction. It is not a reason to conclude the picture is uniformly positive, because the small rise in LDL cholesterol shows the effects are not one-way. As ever with markers rather than outcomes, favourable blood tests are a hypothesis about health, not proof of it.